β-cell function and anti-diabetic pharmacotherapy

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 7, 2007, Pages 518-527

  Del Prato, Stefano ^a   Bianchi, Cristina ^a   Marchetti, Piero ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

cell function; Diabetes; Therapy

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHLORPROPAMIDE; ENZYME ACTIVATOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INCRETIN MIMETIC; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; RO 28 1675; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; VOGLIBOSE;

CLINICAL TRIAL; DIABETIC DIET; DIABETIC MICROANGIOPATHY; DIABETOGENESIS; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 35548957330     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.770     Document Type: Review

References (123)

1. International Diabetes Federation. Facts and Figures. 2004; Available at: http://www.idf.org/home/.
2. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002; 45: 55-12.
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003; 26: 917-932.
4. Koopmanschap M. Coping with Type II diabetes: the patient's perspective. Diabetologia 2002; 45: S18-S22.
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
7. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
8. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
10. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-18.
11. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27(Suppl. 1): S15-S35.
12. European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabet Med 1999; 16: 716-730.
13. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8(Suppl. 1): 40-82.
14. Canadian Diabetes Association. Canadian diabetes association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27(Suppl. 2): S1-S152.
15. Latinamerican Diabetes Association (ALAD). Guidelines for the diagnosis, control and treatment of type 2 diabetes mellitus. Rev As Latinoam Diab 2000; 8(Suppl. 1): 101-167.
16. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 Diabetes: Practical Targets and Treatments (3rd edn), 2002.
17. International Diabetes Federation. Global Guidelines for type 2 Diabetes. 2005; Available at: http://www.idf.org/home/.
18. Haffner SM, Howard G, Mayer E, et al. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes 1997; 46: 63-69.
19. Weyer C, Tataranni PA, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001; 24: 89-94.
20. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
21. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003; 96: 281-288.
22. Tuomilehto J, Lindstrom J, Eriksson JG, et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
23. Knowler WC, Barrett-Connor E, Fowler SE, et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
24. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002; 51(Suppl. 1): S109-S116.
25. Cretti A, Lehtovirta M, Bonora E, et al. Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. Eur J Clin Invest 2001; 31:405-416.
26. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
27. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA, San Antonio Metabolism Study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004; 47: 31-39.
28. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
29. Efanova IB, Zaitsev SV, Zhivotovsky B, et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998; 273: 33501-33507.
30. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-506.
31. Del Guerra S, Marselli L, Lupi R, et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complicat 2005; 19: 60-64.
32. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342.
33. Del Guerra S, Lupi R, Marsell L, et al. Functional and molecular defects of pancreatic islets in humans with type 2 diabetes. Diabetes 2005; 54: 727-735.
34. Del Guerra S, Grupillo M, Masini M, et al. Gliclazide protects human islet beta-cell from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 2007; 23: 234-238.
35. Karam JH, Sanz N, Salamon E, Nolte MS. Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NLDDM. Diabetes 1986; 35: 1314-1320.
36. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; July 20: CD002966.
37. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from Type 2 diabetic patients have functional and survival defects which are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89: 5535-5541.
38. Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic β-cells. Diabetes 2000; 49: 735-740.
39. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002; 51(Suppl. 1): S134-S137.
40. Lupi R, Del Guerra S, Tellini C, et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 1999; 364: 205-209.
41. Leclerc I, Woltersdorf WW, da Silva Xavier G, et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E1023-E1031.
42. Nagi DK, Ali VM, Yudkin JS. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 1996; 13: 753-757.
43. Kitabchi AE, Temprosa M, Knowler WC, et al., The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414.
44. Leiter LA. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. Diabet Med 2005; 22: 963-972.
45. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
46. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000; 17: 40-47.
47. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-1409.
48. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
49. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
50. Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004; 58: 192-200.
51. Nadra AR, Freeman K, Ambery PD. Long-term glycaemic control with rosiglitazone as monotherapy. Diabet Med 2004; 21: 65.
52. Porter LE, Freed MI, Jones NP, Biswas N. Rosiglitazone reduces proinsulin/insulin ratio and improves b-cell function in type 2 diabetes. Diabetologia 2000; 43(Suppl. 1): A192.
53. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal β-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568-576.
54. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
55. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E560-E567.
56. Lupi R, Del Guerra S, Boggi U, Mosca F, Marchetti P, Del Prato S. Pioglitazone protects human islets fromlipotoxicity by improving intracellular lipid metabolism and activating phosphoinositol-3-kinase. Diabetologia 2004; 47(Suppl. 1): A177.
57. Finegood DT, Topp B. β-cell deterioration-prospects for reversal or prevention. Diabetes Obes Metab 2001; 3: S20-S27.
58. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000; 2: 363-372.
59. Ishida H, Takizawa M, Ozawa S, et al. Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: Possible protection of β cells from oxidative stress. Metabolism 2004; 53: 488-494.
60. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
61. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-537.
62. Bennett SM, Agrawal A, Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21: 415-422.
63. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication). Trial Invessigators, Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes mellitus in patients with impaired glucose tolerance orb impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096-1105.
64. Buchanan TA, Xiang AH, Peters RK, et al. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000; 49: 782-788.
65. Kahn SE. Regulation of β-cell function in vivo: from health to disease. Diabetes Rev 1996; 4: 372-389.
66. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-522.
67. Kahn SE, Haffner SM, Heise MA, et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glybutide monotherapy. N Engl J Med 2006; 355: 2427-2443.
68. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19:1190-1193.
69. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23: 1162-1167.
70. Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance. Am J Physiol Endocrinol Metab 2004; 287: E906-E911.
71. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
72. Hotta N, Kakuta H, Sano T, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet Med 1993; 10: 134-138.
73. Göke B, Fuder H, Wieckhorst G, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995; 56: 493-501.
74. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-896.
75. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med 1998; 15: 485-491.
76. Hucking K, Kostic Z, Pox C, et al. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med 2005; 22: 470-476.
77. Efendic S, Portwood N. Overview of incretin hormones. Horm Metab Res 2004; 36: 742-746.
78. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
79. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113:546-593.
80. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
81. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852-858.
82. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004; 36: 761-765.
83. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
84. Barnett AH. Exenatide. Drugs Today (Barc) 2005; 41:563-578.
85. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
86. Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006; 15: 431-442.
87. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
88. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
89. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186-193.
90. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with Type 2 Diabetes. Diabetes Care 2007; May 7: PMID: 17485570.
91. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004; 36: 804-810.
92. Perfetti R, Merkel P. Glucagon-like peptide-1: A major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000; 143: 717-725.
93. Elrick L, Docherty K. Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1. Diabetes 2001; 50: 2244-2252.
94. Buteau J, Roduit H, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-864.
95. Wang Y, Perfetti R, Greig NH, et al. Glucagon-like Peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997; 99: 2883-2889.
96. Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res 2001; 56: 377-399.
97. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48: 2358-2366.
98. Drucker DJ. The glucagon-like peptides. Endocrinology 2001; 142: 521-527.
99. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
100. Jackson RL, Guthrie RA, Murthy DYN. Clinical course of diabetes in children. Mod Probl Paediatr 1975; 12: 22-25.
101. Turner RC, McCarthy ST, Holman RR. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. BMJ 1976; 1: 1252-1254.
102. Andrews WJ, Vasquez B, Nagulesparan M, et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984; 33: 634-642.
103. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356.
104. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032.
105. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-2237.
106. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 39: 900-904.
107. Bernard-Kargar C, Ktorza A. Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 2001; 50(Suppl. 1): S30-S35.
108. Ashcroft FM. Adenosine 5′-triphosphate-sensitive potassium channels. Annu Rev Neurosci 1988; 11: 97-118.
109. Miki T, Iwanaga T, Nagashima K, Ihara Y, Seino S. Roles of ATP-sensitive K+ channels in cell survival and differentiation in the endocrine pancreas. Diabetes 2001; 50(Suppl. 1): S48-S51.
110. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996; 45: 1427-1430.
111. Palmer J. β-cell rest and recovery-does it bring patients with latent autoimmune diabetes in adults to euglycemia? Ann N Y Acad Sci 2002; 958: 89-98.
112. Birnbaum M. Overexpression of the protein kinase Akt/PKB in the mouse beta cell [Abstract]. Beta Cell Biology in the 21st Century; 2001 Nov 26-28; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2001; 10.
113. García-Ocaña A, Vasavada RC, Cebrian A, et al. Transgenic Overexpression of hepatocyte growth factor in the β-cell markedly improves islet function and islet transplant outcomes in mice. Diabetes 2001; 50: 2752-2762.
114. Vasavada RC, Garcia-Ocaña A, Zawalich WS, et al. Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia. J Biol Chem 2000; 275: 15399-15406.
115. Cebrian A, García-Ocaña A, Takane KK, Sipula D, Stewart AF, Vasavada RC. Overexpression of parathyroid hormone-related protein inhibits pancreatic β-cell death in vivo and in vitro. Diabetes 2002; 51: 3003-3013.
116. Accili D. A kinase in the life of the β cell. J Clin Invest 2001; 108: 1575-1576.
117. Bloomgarden ZT. Treatment issues in type 2 diabetes. Diabetes Care 2002; 25: 614-619.
118. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-827.
119. Lingohr M, Dickson LM, McCuaig JF, Hugl SR, Twardzik DR, Rhodes CJ. Activation of IRS-2 mediated signal transduction by IGF-1, but not TGF-β or EGF, augments pancreatic β-cell proliferation. Diabetes 2002; 51: 966-976.
120. Sarabu R, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes-a status review. Curr Opin Drug Discov Devel 2005; 8: 631-637.
121. Printz RL, Granner DK. Tweaking the glucose sensor: adjusting glucokinase activity with activator compounds. Endocrinology 2005; 146: 3693-3695.
122. Del Prato S, Wishner WJ, Gromada J, Schluchter BJ. Beta-cell mass plasticity in type 2 diabetes. Diabetes Obes Metab 2004; 6: 319-531.
123. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.